A- A A+

New Compound Related to Psychedelic Ibogaine Could Treat Addiction, Depression 

A non-hallucinogenic version of the psychedelic drug ibogaine, with potential for treating addiction, depression and other psychiatric disorders, has been developed by researchers at the University of California, Davis. A paper describing the work is published Dec. 9 in Nature. (UCD - University of California Davis, USA, 09.12.2020)

https://www.ucdavis.edu/news/new-compound-related-psychedelic-ibogaine-could-treat-addiction-depression

Reitox-Bericht: Situation illegaler Drogen in Deutschland - Basierend auf dem REITOX-Bericht 2020 an die EMCDDA (Datenjahr 2019/ 2020) 

Franziska Schneider, Krystallia Karachaliou, Nicki-Nils Seitz, Tim Pfeiffer-Gerschel (IFT Institut für Therapieforschung); Maria Friedrich, Bundeszentrale für gesundheitliche Aufklärung (BZgA); Charlotte Tönsmeise, Deutsche Hauptstelle für Suchtfragen(DHS); Werner Sipp, Externer Berater

Basierend auf dem REITOX-Bericht 2020 an die EMCDDA (Datenjahr 2019/ 2020)

https://www.dbdd.de/publikationen/jahresbericht-situation-illegaler-drogen-in-deutschland/

Acute and subacute psychoactive effects of Kambô, the secretion of the Amazonian Giant Maki Frog (Phyllomedusa bicolor): retrospective reports. 

Schmidt, T.T., Reiche, S., Hage, C.L.C. et al. 

Sci Rep 10, 21544 (2020). doi.org/10.1038/s41598-020-78527-4

https://www.nature.com/articles/s41598-020-78527-4

Serie: Global Drug Survey 

Der Global Drug Survey ist die weltweit größte Umfrage zum Drogenkonsum, an der Menschen anonym teilnehmen können. Die Daten der Teilnehmerinnen und Teilnehmer aus Deutschland veröffentlicht ZEIT ONLINE jedes Jahr.

In der Umfrage geht es um die Erfahrungen von Menschen ab 16 Jahren, die psychoaktive Substanzen zu sich nehmen, und ihren Selbsteinschätzungen.

Ziel ist es, Empfehlungen zu erarbeiten, was Konsumentinnen und Konsumenten verschiedener Drogen tun können, um Risiken und Nebenwirkungen zu verringern. (zeit.de, Stand: 02.12.2020)

https://www.zeit.de/serie/global-drug-survey

Psilocybin-Depressionsstudie startet

Mit einer neuen Studie will eine Gruppe von ForscherInnen um Prof. Dr. Gerhard Gründer belastbare Erkenntnisse zur Wirksamkeit und Sicherheit von Psilocybin in der Depressionstherapie gewinnen. (Zentralinstitut für Seelische Gesundheit - News, 19.11.2020

https://www.zi-mannheim.de/institut/news-detail/psilocybin-depressionsstudie-gestartet.html

UNODC. Global Synthetic Drugs Assessment 2020

The Global Synthetic Drugs Assessment 2020 provides an analysis of the global synthetic drugs market. This report presents a global thematic analysis of the key trends and emerging developments of the synthetic drugs market as well as the recent trends in the manufacture of synthetic drugs. (UNODC, Wien, November 2020)

https://www.unodc.org/unodc/en/scientists/2020-global-synthetic-drugs-assessment-main.html

High lifetime, but low current, prevalence of new psychotropic substances (NPS) use in German drug detoxification treatment young inpatients. 

Scherbaum N, Seiffert F, Schifano F, Specka M, Bonnet U, Bender S. 

Prog Neuropsychopharmacol Biol Psychiatry. 2020 Oct 19:110144. doi: 10.1016/j.pnpbp.2020.110144. Epub ahead of print. PMID: 33091544.

Abstract

https://pubmed.ncbi.nlm.nih.gov/33091544/

Ranking the Harm of Psychoactive Drugs Including Prescription Analgesics to Users and Others-A Perspective of German Addiction Medicine Experts. 

Bonnet U, Specka M, Soyka M, Alberti T, Bender S, Grigoleit T, Hermle L, Hilger J, Hillemacher T, Kuhlmann T, Kuhn J, Luckhaus C, Lüdecke C, Reimer J, Schneider U, Schroeder W, Stuppe M, Wiesbeck GA, Wodarz N, McAnally H, Scherbaum N. 

Front Psychiatry. 2020 Oct 26;11:592199. doi: 10.3389/fpsyt.2020.592199. PMID: 33192740; PMCID: PMC7649209.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649209/

Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable experiences

LiridonaGashi, SveinungSandberg, WillyPedersen

International Journal of Drug Policy, Volume 87, January 2021, 102997, doi.org/10.1016/j.drugpo.2020.102997

https://www.sciencedirect.com/science/article/pii/S0955395920303352#!

Psilocybin: Psychedelische Droge lindert in Studie schwere Depressionen

Baltimore – Die zweimalige Gabe von Psilocybin, einem in bestimmten Pilzen enthal­tenen Halluzinogen, hat, unterstützt durch eine Psychotherapie, in einer randomisierten „Proof of Principle“-Studie das Gemüt von Patienten mit mittelschweren bis schweren Depressionen innerhalb eines Tages aufgehellt.

Bei etwa der Hälfte der Patienten wurde laut dem Bericht in JAMA Psychiatry (JAMA, 2020; DOI: 10.1001/jamapsychiatry.2020.3285) eine Remission der Depression erzielt, die über mindestens 8 Wochen anhielt. (aerzteblatt.de, 18.11.2020)

https://www.aerzteblatt.de/nachrichten/118078/Psilocybin-Psychedelische-Droge-lindert-in-Studie-schwere-Depressionen

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. 

Davis AK, Barrett FS, May DG, et al. 

JAMA Psychiatry. Published online November 04, 2020. doi:10.1001/jamapsychiatry.2020.3285

https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2772630

What lies behind the recent revival of therapeutic research on psychedelic drugs? (Webinar)

Prof. Wayne Hall, NSW MEDICINE - National Drug and Alcohol Research Centre, Australien, 08.10.2020, 1:03:42

https://ndarc.med.unsw.edu.au/resource/what-lies-behind-recent-revival-therapeutic-research-psychedelic-drugs

EMCDDA. Psychostimulants to reduce stimulant use — evidence summary 

Summary of the evidence 

Rating: Likely to be beneficial

Substitution therapy has already proved to be effective for smoking and opioid use. Evidence is emerging around the effectiveness of pychostimulants prescription for stimulants related problems. (EMCDDA, Lissabon, 

https://www.emcdda.europa.eu/best-practice/evidence-summaries/psychostimulants-reduce-stimulant-use_en

Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. 

Vollenweider FX, Preller KH. 

Nat Rev Neurosci. 2020 Sep 14. doi: 10.1038/s41583-020-0367-2. Epub ahead of print. PMID: 32929261.

https://www.nature.com/articles/s41583-020-0367-2

USA. Berkeley Center for the Science of Psychedelics

The UC Berkeley Center for the Science of Psychedelics (BCSP) will explore psychedelics as tools for understanding the brain and mind, enhancing well-being, and deepening spirituality. (Berkeley University of California, 2020)

https://bcsp.berkeley.edu/

Effects of Drugs of Abuse on the Blood-Brain Barrier: A Brief Overview. 

Pimentel E, Sivalingam K, Doke M, Samikkannu T. 

Front Neurosci. 2020;14:513. Published 2020 May 21. doi:10.3389/fnins.2020.00513

Effects of Drugs of Abuse on the Blood-Brain Barrier: A Brief Overview. 

Potentially addictive drugs dispensing to patients receiving opioid agonist therapy: a register-based prospective cohort study in Norway and Sweden from 2015 to 2017

Vold JH, Aas C, Skurtveit S, et al

BMJ Open 2020;10:e036860. doi: 10.1136/bmjopen-2020-036860 

Potentially addictive drugs dispensing to patients receiving opioid agonist therapy: a register-based prospective cohort study in Norway and Sweden from 2015 to 2017

Acute poisoning with gamma-hydroxybutyrate. Akutt forgiftning med gammahydroksybutyrat. 

Aronsen AC, Brekke M, Vallersnes OM. 

Tidsskr Nor Laegeforen. 2020;140(10):10.4045/tidsskr.19.0780. Published 2020 Jun 29.

https://tidsskriftet.no/en/2020/06/kort-rapport/acute-poisoning-gamma-hydroxybutyrate

One Is Not Enough: Understanding and Modeling Polysubstance Use. 

Crummy EA, O'Neal TJ, Baskin BM, Ferguson SM. 

Front Neurosci. 2020;14:569. Published 2020 Jun 16. doi:10.3389/fnins.2020.00569

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309369/

Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia: A Systematic Review and Meta-analysis.

Beck K, Hindley G, Borgan F, et al. 

JAMA Netw Open. 2020;3(5):e204693. doi:10.1001/jamanetworkopen.2020.4693

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2766225

Why Isotonitezene Is Not Yet the “New Fentanyl” 

In the span of about a year, isotonitazene, a novel psychoactive substance (NPS), went from being practically unheard of to being implicated in a fatal overdose spike in the Midwest. While some researchers and media reports are warning about the emergence of the designer drug, one harm reductionist from the region cautions against singling it out. (Filter Magazine, USA, 21.05.2020)

https://filtermag.org/isotonitezene/

An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions.

Schifano F, Chiappini S, Corkery JM, Guirguis A.

Int J Neuropsychopharmacol. 2019 Apr 1;22(4):270-277. doi: 10.1093/ijnp/pyz007.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441128/

The problem of alpha-PVP in Russia and other post-Soviet states
On Russian YouTube, there are videos of alpha-PVP users, acting in bizarre and uncontrollable ways. It’s just one small sign of a vast, hidden epidemic. Read this report from Sam Iravani! (Drug Reporter, Ungarn, 24.03.2020)

https://drogriporter.hu/en/alphapvp/

Hirnforschung: Ritalin macht nicht klüger, motiviert aber zum Lernen

Providence, Rhode Island − Die Einnahme von Methylphenidat, besser bekannt unter dem Markennamen Ritalin, verbessert nicht die kognitiven Fähigkeiten, sie könnte allerdings die Motivation fördern, sich schwierigen Aufgaben zu stellen, weil die Belohnung nach der erfolgreichen Absolvierung als stärker empfunden wird. (aerzteblatt.de, 31.03.2020)

https://www.aerzteblatt.de/nachrichten/111273/Hirnforschung-Ritalin-macht-nicht-klueger-motiviert-aber-zum-Lernen

USA. Drugs of Abuse - A DEA Resource Guide: 2020 EDITION 

Drugs of Abuse, A DEA Resource Guide, is designed to be a reliable resource on the most commonly abused and misused drugs in the United States. This comprehensive guide provides important information about the harms and consequences of drug use by describing a drug’s effects on the body and mind, overdose potential, origin, legal status, and other key facts. (Drug Enforcement Administration, U.S. Department of Justice, April 2020) 

https://www.getsmartaboutdrugs.gov/sites/getsmartaboutdrugs.com/files/publications/Drugs%20of%20Abuse%202020-Web%20Version-508%20compliant.pdf

Drugs in Iran: A New IranWire Series 

The illicit drugs trade in Iran has shaped countless lives, exacerbated by punitive and misguided polices that have left some of society’s most vulnerable in the cold. In an exclusive new series for IranWire, academic Dariush Farahani lifts the lid on an under-reported contemporary crisis. (Iran wire, Iran, 23.03.2020)

https://iranwire.com/en/features/6840

Kenia. Meet Beauty Therapist Saving Female Heroin Addicts 

But this isn’t just any beauty parlour. The women who seek Naima’s services are addicted to heroin, or they’re recovering.

Housed in the Reachout Centre Trust, which helps Mombasa residents fight drug addiction, it opened last year with a view to attracting more female users to its services that include HIV testing, counselling, methadone treatment and cervical cancer screening. (The Guardian, UK, 18.03.20209

https://www.theguardian.com/global-development/2020/mar/18/you-are-beautiful-the-kenyan-beauty-parlour-serving-female-heroin-users

Neuroethical issues in cognitive enhancement: Modafinil as the example of a workplace drug?

Brühl AB, d'Angelo C, Sahakian BJ.

Brain Neurosci Adv. 2019 Feb 15;3:2398212818816018. doi: 10.1177/2398212818816018. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058249/

Cardiovascular and Autonomic Responses to Energy Drinks-Clinical Implications.

Somers KR, Svatikova A.

J Clin Med. 2020 Feb 5;9(2). pii: E431. doi: 10.3390/jcm9020431. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073550/